New drug targets for genomic cancer therapy: successes, limitations, opportunities and future challenges.
Cancer drug therapy is undergoing a major transition from the previous pregenomic cytotoxic era to the new postgenomic era. Future mechanism-based therapeutic agents will increasingly be designed to act on molecular targets that are causally involved in the malignant progression of human cancers. Such agents are predicted to show greater therapeutic selectivity for cancer versus normal cells. New cancer drug targets are identified and validated in various ways. The determination of the normal human genome sequence, followed by that of multiple cancer genomes, is accelerating target discovery. Other new technologies, particularly high throughput screening, combinatorial chemistry and gene expression microarrays, are increasing the speed and efficiency of drug development. Examples of new molecular therapeutics showing promising activity in the clinic include Herceptin, Glivec and Iressa. However, many challenges remain as we test the vision of individualised combinatorial genome-based therapy, using drugs targeted to every significant molecular abnormality in cancer.
Workman
P
P
CRC Centre for Cancer Therapeutics, Institute for Cancer Research, Sutton, Surrey, SN2 5NG, UK. paulw@icr.ac.uk
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000627:therapeutic use; D015195:Drug Design; D004354:Drug Screening Assays, Antitumor; D005544:Forecasting; D020869:Gene Expression Profiling; D015316:Genetic Therapy / Q000379:methods; D015894:Genome, Human; D006801:Humans; D009369:Neoplasms / Q000235:genetics* / Q000628:therapy*
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D019496:Cancer Vaccines